Integra LifeSciences Holdings
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $38.91
- Today's High:
- $39.38
- Open Price:
- $39.21
- 52W Low:
- $37.36
- 52W High:
- $60.69
- Prev. Close:
- $39.48
- Volume:
- 491959
Company Statistics
- Market Cap.:
- $3.21 billion
- Book Value:
- 20.689
- Revenue TTM:
- $1.55 billion
- Operating Margin TTM:
- 16.44%
- Gross Profit TTM:
- $982.03 million
- Profit Margin:
- 8.5%
- Return on Assets TTM:
- 4.22%
- Return on Equity TTM:
- 7.85%
Company Profile
Integra LifeSciences Holdings had its IPO on 1995-08-16 under the ticker symbol IART.
The company operates in the Healthcare sector and Medical Devices industry. Integra LifeSciences Holdings has a staff strength of 3,722 employees.
Stock update
Shares of Integra LifeSciences Holdings opened at $39.21 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $38.91 - $39.38, and closed at $39.12.
This is a -0.91% slip from the previous day's closing price.
A total volume of 491,959 shares were traded at the close of the day’s session.
In the last one week, shares of Integra LifeSciences Holdings have slipped by -8.51%.
Integra LifeSciences Holdings's Key Ratios
Integra LifeSciences Holdings has a market cap of $3.21 billion, indicating a price to book ratio of 2.8275 and a price to sales ratio of 3.0074.
In the last 12-months Integra LifeSciences Holdings’s revenue was $1.55 billion with a gross profit of $982.03 million and an EBITDA of $374.99 million. The EBITDA ratio measures Integra LifeSciences Holdings's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Integra LifeSciences Holdings’s operating margin was 16.44% while its return on assets stood at 4.22% with a return of equity of 7.85%.
In Q2, Integra LifeSciences Holdings’s quarterly earnings growth was a negative -90.7% while revenue growth was a negative 4.2%.
Integra LifeSciences Holdings’s PE and PEG Ratio
- Forward PE
- 16.1812
- Trailing PE
- 24.8302
- PEG
- 1.3476
Its diluted EPS in the last 12-months stands at $1.59 per share while it has a forward price to earnings multiple of 16.1812 and a PEG multiple of 1.3476. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Integra LifeSciences Holdings’s profitability.
Integra LifeSciences Holdings stock is trading at a EV to sales ratio of 3.8835 and a EV to EBITDA ratio of 16.4345. Its price to sales ratio in the trailing 12-months stood at 3.0074.
Integra LifeSciences Holdings stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.78 billion
- Total Liabilities
- $377.50 million
- Operating Cash Flow
- $-15548000.00
- Capital Expenditure
- $15.55 million
- Dividend Payout Ratio
- 0%
Integra LifeSciences Holdings ended 2024 with $3.78 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.78 billion while shareholder equity stood at $1.68 billion.
Integra LifeSciences Holdings ended 2024 with $70.65 million in deferred long-term liabilities, $377.50 million in other current liabilities, 909000.00 in common stock, $907.53 million in retained earnings and $1.04 billion in goodwill. Its cash balance stood at $309.19 million and cash and short-term investments were $309.19 million. The company’s total short-term debt was $110,262,000 while long-term debt stood at $1.33 billion.
Integra LifeSciences Holdings’s total current assets stands at $1.05 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $258.66 million compared to accounts payable of $99.77 million and inventory worth $354.29 million.
In 2024, Integra LifeSciences Holdings's operating cash flow was $-15548000.00 while its capital expenditure stood at $15.55 million.
Comparatively, Integra LifeSciences Holdings paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $39.12
- 52-Week High
- $60.69
- 52-Week Low
- $37.36
- Analyst Target Price
- $49.67
Integra LifeSciences Holdings stock is currently trading at $39.12 per share. It touched a 52-week high of $60.69 and a 52-week low of $60.69. Analysts tracking the stock have a 12-month average target price of $49.67.
Its 50-day moving average was $42.93 and 200-day moving average was $50.36 The short ratio stood at 3.9 indicating a short percent outstanding of 0%.
Around 1314.6% of the company’s stock are held by insiders while 9234.5% are held by institutions.
Frequently Asked Questions About Integra LifeSciences Holdings
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.